Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Respiratory Disorders

Treatments: Drug: Salmeterol and Fluticasone

Study type: Observational

Funder types: Industry

Identifiers

NCT01395849

112277

Details and patient eligibility

About

The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.

Enrollment: 2,116 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must use fluticasone and salmeterol for the first time

Exclusion criteria

• Patients with hypersensitivity to salmeterol and fluticasone
• Patients with infection which salmeterol and fluticasone is not effective
• Patients with deep mycosis

Trial design

2,116 participants in 1 patient group

Patients prescribed fluticasone and salmeterol

Description:

Patients with asthma prescribed fluticasone and salmeterol during study period

Treatment:

Drug: Salmeterol and Fluticasone